Skip to content

Search

Showing results for "1"

From Diagnosis to Consumer Representative – Danae’s journey to making a difference

Recognising the signs of type 1 diabetes (T1D) can be tricky. Often put down to growing pains, a virus or “something going around”, a diagnosis can take some time if children aren’t severely sick and attend an emergency department.

Embrace Big Idea 2023 Winner

Congratulations to our Rio Tinto Children's Diabetes Centre mental health and wellbeing team who, in partnership with the Embrace childhood trauma

Sleepovers and diabetes

Love them or hate them, but sleepovers are a popular pastime for children. Understandably, parents of children living with type 1 diabetes might be hesitant to leave them in someone else’s care for an extended period, but there are ways to ensure that everyone is prepared for a safe experience.

Prime Minister visits The Kids

We welcomed the Prime Minister Malcolm Turnbull, Minister for Finance Mathias Cormann and Minister for Foreign Affairs Julie Bishop to the Institute.

Wellbeing partnership building resilience after medical trauma

Helping children build resilience and cope with the trauma associated with medical emergencies and chronic health conditions is the focus of a promising pilot program being undertaken by The Kids Research Institute Australia.

Top-up funding announced to fast-track clinical trials of Spritz-OM

Researchers developing a nasal therapy to prevent childhood ear infections and reduce overuse of antibiotics have received $300,000 in top-up funding.

Impact of Repeat Pertussis Vaccination on Infant and Maternal Antibody Quality

Ruth Peter Thornton Richmond PhD MBBS MRCP(UK) FRACP Co-head, Bacterial Respiratory Infectious Disease Group (BRIDG) Head, Vaccine Trials Group

COVID-19

The year 2020 has been marked by possibly the greatest health challenge to face modern society. The emergence of COVID-19 as a novel human pathogen

Antibody responses against influenza A decline with successive years of annual influenza vaccination

Influenza vaccine effectiveness and immunogenicity can be compromised with repeated vaccination. We assessed immunological markers in a cohort of healthcare workers (HCW) from six public hospitals around Australia during 2020-2021.

Evaluating the effectiveness of the 13-valent pneumococcal conjugate vaccine and clinical and demographic characteristics on pneumococcal carriage density in young children

High nasopharyngeal pneumococcal carriage density is associated with severe pneumonia; however, little is known about factors that affect pneumococcal carriage density including pneumococcal vaccination. We describe pneumococcal density by clinical and demographic factors, and effect of 13-valent pneumococcal conjugate vaccine (PCV13) on density in Papua New Guinea (PNG), Lao People’s Democratic Republic (Lao PDR) and Mongolia, 3–6 years following national PCV13 introduction.